StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN)

Investment analysts at StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a note issued to investors on Saturday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners initiated coverage on Lipocine in a research note on Tuesday, September 24th. They issued a “buy” rating and a $10.00 target price for the company.

Lipocine Stock Performance

Shares of LPCN opened at $4.54 on Friday. Lipocine has a fifty-two week low of $2.38 and a fifty-two week high of $11.79. The firm has a market cap of $24.29 million, a price-to-earnings ratio of -5.97 and a beta of 1.18. The firm has a 50 day moving average price of $5.08 and a 200-day moving average price of $5.62.

Lipocine (NASDAQ:LPCN) last issued its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter. As a group, equities research analysts predict that Lipocine will post -0.78 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP purchased a new position in Lipocine Inc. (NASDAQ:LPCN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine as of its most recent SEC filing. Institutional investors and hedge funds own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.